Browsing Tag
LYMPHIR
3 posts
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
March 13, 2026
Citius Oncology (Nasdaq: CTOR) bets on Verix AI to supercharge LYMPHIR’s commercial rollout in CTCL
Find out how Citius Oncology is leveraging Verix AI to power the commercial launch of LYMPHIR and accelerate uptake in CTCL.
November 23, 2025
Citius Oncology bets on AI-powered sales strategy to fast-track LYMPHIR cancer drug launch
Citius Oncology launches an AI-powered platform to boost LYMPHIR’s commercial debut in CTCL, reshaping oncology sales strategies with precision targeting.
August 22, 2025